AlphAIAlphAI — Financial news for AI agents
tradingview.com$IONS

Key facts: Ionis Q3 Loss, Mixed Trial Results; HIBSAGO Wins Approvals

Ionis Pharmaceuticals (IONS) reported Q3 2026 revenue of $243M, up 54.8% YoY, and a net loss of $110M. It lowered TRYNGOLZA sales guidance to $50M. Mixed trial results: sefaxersen and ulefnersen showed positive data, while pelacarsen and eplontersen missed Phase 3 goals. HIBSAGO won U.S., Japan, and Canada approvals, triggering a $30M milestone. The average 12-month price target fell to $83.38, with a consensus Buy rating.

Original reporting
tradingview.com
Published Nov 10, 2026, 8:00 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 10, 2026, 8:09 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Key facts: Ionis Q3 Loss, Mixed Trial Results; HIBSAGO Wins Approvals — source image
Source · tradingview.com
Decision brief

The 30-second read

$IONSBearishHigh
01

Why it matters

The earnings miss and mixed trial data create short‑term downside risk, while the HIBSAGO approval adds a modest positive catalyst.

02

Market read

First‑report earnings and trial news for a mid‑cap biotech, likely to move the stock at open.

03

What to watch

Potential future data readouts for pelacarsen and eplontersen may improve outlook later in the year.

Relevance 8/10Novelty 8/10Timing: pre-market today

Background

Ionis Pharmaceuticals (NASDAQ: IONS) is a biotech focused on RNA‑targeted therapies. The company released its Q3 earnings and disclosed mixed Phase 3 trial results for several candidates, plus a new regulatory approval milestone.

Company-level read

Ticker impact

$IONSBearishHigh confidence
Context

Ionis reported Q3 2026 revenue of $243M, a $110M net loss, mixed Phase 3 trial results and a $30M HIBSAGO milestone.

Expected impact

likely pressure as investors digest the loss and trial setbacks, offset by modest upside from the new approval milestone

Evidence & confidence

Earnings miss and negative trial data are immediate catalysts; the $30M milestone is smaller relative to revenue.

Market effects

Sector

Biotech sector may see broader scrutiny of Phase 3 trial outcomes.

Regional

US biotech investors likely adjust positions ahead of market open.

Global

Limited to companies with similar rare‑disease pipelines.

Counterpoint

What could challenge this read

The HIBSAGO approval and royalty stream could outweigh the loss, supporting a short‑term rally.

Key entities

  • company
    Ionis Pharmaceuticals, Inc.

    Biotech firm reporting Q3 results and trial updates.

Read at source← All news

StoryIonis cuts TRYNGOLZA outlook after slower launch despite Q3 revenue growth

Also covered by

4 outlets

Related articles

$IONSHighAI 8/10

Here's Why Ionis Pharmaceuticals' Stock is Down 28.5% Post Q3 Earnings

Ionis Pharmaceuticals' stock fell 28.5% post-Q3 2026 earnings despite beating estimates. Investors were disappointed by slower-than-expected Tryngolza sales and reduced full-year guidance to $50M. Wainua royalties also missed estimates. Dawnzera sales grew 40% sequentially. Ionis pushed back positive cash flow target to 2029. Competition from Arrowhead and Alnylam adds to concerns.

tradingview.com
$TEVAHigh

FDA Drug Approvals In October 2026

The FDA approved five drugs in October 2026: Teva's Weltruza (TEVA) for schizophrenia, Asahi Kasei's Hovilpri (3407.T) for herpes, Alcon's Brytly (ALC) for eye redness, GSK and Ionis' Hibsago (GSK, IONS) for hepatitis B, and Xbrane and STADA's Lucamzi for retinal diseases. Key details include efficacy, pricing, and competitor landscape.

rttnews.com
$IONSHighAI 8/10

Ionis Pharmaceuticals Inc (IONS) (Q3 2026) Earnings Call Highlights: DAWNZERA Momentum

Ionis Pharmaceuticals (IONS) reduced 2026 revenue guidance to $50M due to slower TRYNGOLZA launch and Phase III setbacks. Cash flow breakeven delayed to 2029. Only 24% of prescribers have written multiple prescriptions. Management cited education needs and payer coverage as key factors. Q3 cash position was $1.9B, with $1.6B expected by year-end. 2027 guidance deferred to February call.

finance.yahoo.com
$IONSHighAI 8/10

Ionis (IONS) Q3 2026 Earnings Call Transcript

Ionis (IONS) reported Q3 2026 earnings, highlighting approvals and positive trial results. They lowered TRYNGOLZA's 2026 revenue guidance to $50M due to a slower launch. Despite this, they remain confident in its long-term potential. The company is refining launch tactics and expanding payer access. Other drugs like DAWNZERA and ZANVASTRO were also discussed.

finance.yahoo.com